Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial
View ORCID ProfileAndrew A. Lover
doi: https://doi.org/10.1101/2020.03.22.20040949
Andrew A. Lover
Department of Biostatistics and Epidemiology, University of Massachusetts-Amherst, Amherst, MA,

Data Availability
Data sources, statistical code, and supporting documents are available here: https://github.com/andrewlover/HCQ_AZ_COVID_19
Posted April 10, 2020.
Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial
Andrew A. Lover
medRxiv 2020.03.22.20040949; doi: https://doi.org/10.1101/2020.03.22.20040949
Subject Area
Subject Areas
- Addiction Medicine (62)
- Allergy and Immunology (141)
- Anesthesia (44)
- Cardiovascular Medicine (408)
- Dermatology (47)
- Emergency Medicine (141)
- Epidemiology (4809)
- Gastroenterology (177)
- Geriatric Medicine (70)
- Health Economics (187)
- Health Informatics (621)
- Health Policy (314)
- Hematology (84)
- HIV/AIDS (155)
- Medical Education (91)
- Medical Ethics (24)
- Nephrology (73)
- Neurology (677)
- Nursing (41)
- Nutrition (110)
- Oncology (437)
- Ophthalmology (138)
- Orthopedics (36)
- Otolaryngology (88)
- Pain Medicine (35)
- Palliative Medicine (15)
- Pathology (127)
- Pediatrics (193)
- Public and Global Health (1796)
- Radiology and Imaging (321)
- Respiratory Medicine (255)
- Rheumatology (86)
- Sports Medicine (61)
- Surgery (100)
- Toxicology (23)
- Transplantation (28)
- Urology (37)